Steinhart Richard I 4
4 · BioXcel Therapeutics, Inc. · Filed Mar 16, 2026
Research Summary
AI-generated summary of this filing
BioXcel (BTAI) CFO Richard Steinhart Receives Shares via RSU Conversion
What Happened Richard I. Steinhart, Chief Financial Officer of BioXcel Therapeutics (BTAI), converted restricted stock units (RSUs) into 68 shares of common stock: 33 shares on March 14, 2026 and 35 shares on March 15, 2026. The Form 4 reports these as derivative conversions (transaction code M). No cash was reported as paid or received for the conversions (reported $0).
Key Details
- Transaction dates: March 14, 2026 (33 shares) and March 15, 2026 (35 shares).
- Total shares received: 68 shares.
- Reported consideration: $0 (conversion of RSUs/derivative; reported as disposed/converted).
- Footnotes: F1–F3 indicate these were RSUs (each RSU = right to 1 share) granted on 3/14/2022 (521 RSUs) and 3/15/2023 (562 RSUs) with scheduled vesting; these conversions represent vested portions of those grants.
- Shares owned after the transaction: not specified in the provided excerpt.
- Filing: Report filed March 16, 2026 (appears timely based on transaction dates).
Context This filing documents the vesting/conversion of previously granted RSUs into common stock, not an open-market purchase or sale. Converting RSUs into shares is routine when awards vest; it does not by itself signal a buy or sell intent. Because the report shows conversion (derivative exercise/settlement) with $0 consideration, check future filings for any subsequent sales or tax-withholding share dispositions.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-03-14+33→ 6,610 total - Exercise/Conversion
Common Stock
[F1]2026-03-15+35→ 6,645 total - Exercise/Conversion
Restricted Stock Units
[F1][F2]2026-03-14−33→ 97 total→ Common Stock (33 underlying) - Exercise/Conversion
Restricted Stock Units
[F1][F3]2026-03-15−35→ 247 total→ Common Stock (35 underlying)
Footnotes (3)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
- [F3]On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.